SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts. The inaugural members of the SAB include Alterome co-founder Ryan Corcoran, M.D., Ph.D., Benjamin Cravatt, Ph.D., Paul Workman, Ph.D., and Keith Flaherty, M.D. The SAB will work closely with the Alter
Click here to view original post
Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts
